Autoantibody Diversity Is Augmented in Women with Breast Cancer and Is Related to the Stage of the Disease

Author:

Pérez-Hernández Jesús1,León-Díaz Rosalba2,Zentella Alejandro3,Lamoyi Edmundo4,Esquivel-Velázquez Marcela5ORCID,Barranca-Enríquez Antonia6,Romo-González Tania2ORCID

Affiliation:

1. Unidad de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, ZP, Mexico

2. Área de Biología y Salud Integral, Instituto de Investigaciones Biológicas, Universidad Veracruzana, Xalapa 91190, ZP, Mexico

3. Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, ZP, Mexico

4. Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, ZP, Mexico

5. Laboratorio de Proteómica, Dirección de Investigación, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, ZP, Mexico

6. Centro de Estudios y Servicios en Salud, Universidad Veracruzana, Veracruz 91700, ZP, Mexico

Abstract

Breast cancer (BC) is the most frequent malignant neoplasia and leading cause of cancer mortality for women. A timely diagnosis of BC is crucial to ensure the best chances of survival. Among the various screening tools for BC, antibodies directed towards self-antigens or tumor-associated antigens (autoantibodies) have emerged as an alternative to image-based screening modalities. However, little attention has been paid to the global diversity of autoantibodies. This work aimed to analyze the diversity of autoantibodies reactive to antigens expressed by the BC cell line T47D in the sera of Mexican women with BC, benign breast pathology (BBP), or without breast pathology (WBP). We found that the diversity of antibodies in the sera was higher in the BC and BBP groups than in the WBP group. Likewise, the diversity changed with the progression of BC. Our results show and measure the complexity of the antibody response in breast health and disease.

Funder

Consejo Nacional de Ciencia y Tecnología, México

PAPIIT, Dirección General de Asuntos del Personal Académico (DGAPA), UNAM

Publisher

MDPI AG

Reference31 articles.

1. (2022, March 15). Global Cancer Observarory. Available online: https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=16&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0.

2. National Institute of Statistics, Geography and Informatics (2022, March 15). 2021, Mexico. Statistics Regarding the World Day of the Fight Against Breast Cancer (October 19). Press Release no. 571/21. 18 October 2021. Available online: https://www.inegi.org.mx/contenidos/saladeprensa/aproposito/2021/EAP_LUCHACANCER2021.pdf.

3. Prognostic factors in patients with breast cancer and brain metastasis as the first site of recurrence;Cabrera;Public Health Mex.,2018

4. Qiu, J., Keyser, B., Lin, Z.T., and Wu, T. (2018). Autoantibodies as Potential Biomarkers in Breast Cancer. Biosensors, 8.

5. IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways;Rosskopf;Oncotarget,2019

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3